Sonnet BioTherapeutics Holdings, Inc. financial data

Symbol
SONN on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Overlook Center, Suite 102, Princeton, NJ
State of incorporation
DE
Fiscal year end
September 30
Former names
Chanticleer Holdings, Inc. (to 3/31/2020), TULVINE SYSTEMS INC (to 3/31/2005)
Latest financial report
10-K - Q3 2024 - Dec 17, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 146 % +27.6%
Debt-to-equity 155 % -72.8%
Return On Assets -150 % +32.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.01M shares -2.02%
Common Stock, Shares, Outstanding 650K shares +197%
Entity Public Float 46.2M USD +532%
Common Stock, Value, Issued 65 USD +195%
Weighted Average Number of Shares Outstanding, Basic 655K shares +405%
Weighted Average Number of Shares Outstanding, Diluted 655K shares +405%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 129K USD -49.8%
Research and Development Expense 5.74M USD -51.4%
General and Administrative Expense 6.13M USD -14%
Operating Income (Loss) -11.8M USD +36.9%
Net Income (Loss) Attributable to Parent -7.44M USD +60.5%
Earnings Per Share, Basic -11.4 USD/shares +92.2%
Earnings Per Share, Diluted -11.4 USD/shares +92.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 149K USD -93.4%
Assets, Current 2.12M USD -55.3%
Property, Plant and Equipment, Net 20.5K USD -38.5%
Operating Lease, Right-of-Use Asset 123K USD -36.3%
Other Assets, Noncurrent 494K USD +19.3%
Assets 2.77M USD -49%
Accounts Payable, Current 2.18M USD -0.84%
Accrued Liabilities, Current 3.32M USD +3.47%
Liabilities, Current 3.21M USD -41.9%
Operating Lease, Liability, Noncurrent 46.6K USD -64.4%
Liabilities 3.26M USD -42.4%
Retained Earnings (Accumulated Deficit) -118M USD -6.75%
Stockholders' Equity Attributable to Parent -486K USD -115%
Liabilities and Equity 2.77M USD -49%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.09M USD +47.7%
Net Cash Provided by (Used in) Financing Activities 3.84M USD -15.9%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 650K shares +197%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 747K USD
Deferred Tax Assets, Valuation Allowance 36.5M USD -1.67%
Deferred Tax Assets, Gross 36.5M USD -1.73%
Operating Lease, Liability 131K USD -35.8%
Depreciation 3.21K USD 0%
Lessee, Operating Lease, Liability, to be Paid 144K USD -39.4%
Operating Lease, Liability, Current 84.3K USD +15.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 48.2K USD -49.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 95.5K USD +2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.8K USD -61.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 48.2K USD -49.5%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD -4.44%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 117M USD +6.52%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39.5K USD -36.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%